EFFECT OF HUMAN PAPILLOMAVIRUS INFECTION ON IN-VITRO FERTILIZATION OUTCOMES
DOI: 10.22138/2500-0918-2018-15-6-757-764
N.V. Bashmakova, A.A. Osipenko, T.V. Lisovskaya,
V.N. Lokshin, E.N. Mayasina, D.F. Salimov
Ural Research Institute for Maternal and Child Welfare, Yekaterinburg, Russian Federation;
Clinical Institute of Reproductive Medicine, LLC, Yekaterinburg, Russian Federation;
“Persona” International Clinical Centre for Reproductive Medicine, Almaty, Republic of Kazakhstan
Abstract. Objective. To assess the impact of human papillomavirus infection on the effectiveness of infertility treatment using a retrospective analysis of the assisted reproductive technology outcomes. Subject and methods. A case-control (or retrospective) study was conducted to analyse 120 medical records of infertile women who underwent IVF treatment. Patients were divided into two groups consisting of 60 people each: an experimental group, consisting of infertile women being HPV carriers (HPV+), and a control group, consisting of infertile women without HPV infection (HPV-). Results. In the experimental (HPV+) group pregnancy was clinically confirmed in 21.7% of women, while in the control (HPV-) group in 40% of women, р =0.047. No difference was observed between HPV+ and HPV- groups in the number or quality of oocytes, zygotes and embryos. Conclusion. In case of female patients being HPV carriers the efficiency of in vitro fertilization programs is substantially lower than for HPV-negative patients. Taking into account the established absence of the impact of HPV infection on the number and quality of embryos, this fact may be explained by possible viral damage to trophoblast cells and abnormal embryo implantation process. However, more research is needed to further investigate this issue.
Keywords: human papillomavirus, in vitro fertilization, pregnancy
There is no conflict of interest.
Contact details of the corresponding author:
Anna A. Osipenko
osipenko_aa@inbox.ru
Received 29.10.2018
For citation:
Bashmakova N.V., Osipenko A.A., Lisovskaya T.V., Lokshin V.N., Mayasina E.N., Salimov D.F. Effect of human papillomavirus infection on in-vitro fertilization outcomes. Vestn. Ural. Med. Akad. Nauki. = Journal of Ural Medical Academic Science. 2018, Vol. 15, no. 6, pp. 757–764. DOI: 10.22138/2500-0918-2018-15-6-757-764 (In Russ)
REFERENCES
1. G.M. Mzarelua, N.M. Nazarova, M.E. Nekrasova et al. Prevalence of HPV types in patients with cervical intraepithelial neoplasia of different severity Obstetrics and Gynecology. 2018. No. 4. pp. 94-100. https://dx.doi.org/10.18565/aig.2018A94- 100 (In Russ).
2. V.F. Dolgushina, O.S. Abramovsky. Prevalence of various genotypes of human papillomavirus in cervical pathology. Obstetrics and Gynecology. 2011. No. 4. pp. 69-74. (In Russ).
3. K. Zacharis, CI. Messini, G. Anifandis et al. Medicina (Kaunas). Human Papilloma Virus (HPV) and Fertilization: A Mini Review. 2018 Jul 27; 54(4). pii: E50. doi: 10.3390/medicina54040050.
4. A. Perino, L. Giovannelli, R. Schillaci et al. Human papillomavirus infection in couples undergoing in vitro fertilization procedures: impact on reproductive outcomes. Fertil Steril. 2011. Vol. 95(5). pp. 1845¬1848. DOI:10.1016/j.fertnstert.2010.11.047
5. R. Yang, Y. Wang, J. Qiao et al. Does human papillomavirus infection do harm to in-vitro fertilization outcomes and subsequent pregnancy outcomes? Chinese Medical Journal. 2013. Vol. 126(4). pp. 683-687.
6. I. Oborna, H. Ondryasova, B. Zborilova, et al. Does presence of human papillomavirus (HPV) infection influence the results of in vitro fertilization (IVF) treatment? Fertility and Sterility. 2016. Vol. 106(3). pp. 335-336.
7. C.E. Depuydt, J. Beert, E. Bosmans, G. Salembier. Human Papillomavirus (HPV) virion induced cancer and subfertility, two sides of the same coin. Facts Views Vis Obgyn. 2016 Dec; 8(4):211-222.
8. N. Pereira, K.M. Kucharczyk, J. L. Estes et al. Human Papillomavirus Infection, Infertility, and Assisted Reproductive Outcomes. J Pathol. 2015. 2015:578423. doi: 10.1155/2015/578423. Epub 2015 Nov 1.
9. Siristatidis C, Vaidakis D, Sertedaki E, Martins W.P. Effect of human papilloma virus infection on in- vitro fertilization outcome: systematic review and meta¬analysis. Ultrasound Obstet Gynecol. 2018. Jan; 51(1). pp. 87¬93. DOI:10.1002/uog.17550
10. Manini I, Montomoli E. Epidemiology and prevention of Human Papillomavirus. Ann Ig. 2018. Jul-Aug; 30(4 Supple 1). pp. 28-32. doi: 10.7416/ ai.2018.2231.
11. Nayar R, Wilbur D.C.The Pap test and Bethesda 2014. Cancer Cytopathol. 2015. May; 123(5) pp. 271-81. doi: 10.1002/cncy.21521. Epub 2015 May 1.
12. ACOG Practice Bulletin No. 157 Summary: Cervical Cancer Screening and Prevention. Obstetrics & Gynecology. 2016. Vol. 127 (Issue 1). pp. 185-187. DOI:10.1097/AOG.0000000000001256.
13. Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. АLPHAScientists In Reproductive Medicine; ESHRE Special Interest Group Embryology. Reprod Biomed Online. 2011 Jun; 22(6):632-46. doi: 10.1016/j.rbmo.2011.02.001. Epub 2011 Apr 11.
14. L. J. Hong, B. T. Oshiro, P. J. Chan. HPV-16 exposed mouse embryos: a potential model for pregnancy wastage. Archives of Gynecology and Obstetrics. 2013. Vol. 287(6). pp. 1093-1097. DOI:10.1007/s00404-013- 2711-5
15. M. Noventa, A. Andrisani, S. Gizzo et al. Is it time to shift the attention on early stages embryo development to avoid inconclusive evidence on HPV-related infertility: debate and proposal. Reprod Biol Endocrinol. 014. Vol. 12. p. 48. DOI:10.1186/1477-7827-12-48
16. Ambuhl L.M.M., Villadsen A.B., Baandrup U., et al. HPV16 E6 and E7 Upregulate Interferon- Induced Antiviral Response Genes ISG15 and IFIT1 in Human Trophoblast Cells. Pathogens. 2017. Sep 3;6(3). pii: E40. doi: 10.3390/pathogens6030040.
17. Hong L.J., Oshiro B.T., Chan P.J. HPV-16 exposed mouse embryos: a potential model for pregnancy wastage. Arch Gynecol Obstet. 2013. Jun; 287(6):1093-7. doi: 10.1007/s00404-013-2711-5. Epub 2013 Jan 11.
Authors:
Nadezhda V. Bashmakova
Dr. Sci. (Med.), Professor, Deputy Director of Research Work
Ural Research Institute for Maternal and Child Welfare
Repina str. 1, Yekaterinburg, Russian Federation, 620028 dr@niiomm.ru
Anna A. Osipenko
Gynecologist, Clinical Institute of Reproductive Medicine, LLC
Postgraduate student,
Ural Research Institute for Maternal and Child Welfare
B. Yeltsin Str., 3, of. 503, Yekaterinburg, Russian Federation, 620014
osipenko_aa@inbox.ru
Tatyana V. Lisovskaya
Dr. Sci. (Med.), Leading Researcher of Clinical Institute of Reproductive Medicine, LLC,
Deputy Director for Science
Ural Research Institute for Maternal and Child Welfare
B. Yeltsin Str., 3, of. 503, Yekaterinburg, Russian Federation, 620014
tv.lis@mail.ru
Vyacheslav N. Lokshin
Dr. Sci. (Med.), Professor, Corresponding Member of NAS of Kazakhstan, President of Reproductive Medicine Association of Kazakhstan, Director of “Persona” International Clinical Centre for Reproductive Medicine
Utepova Str., 32, Almaty, Kazakhstan
v_lokshin@persona-ivf.kz
Elena N. Mayasina
Cand. Sci. (Med.), Deputy General Director for Clinical Work
Clinical Institute of Reproductive Medicine, LLC
B. Yeltsin Str., 3, of. 503, Yekaterinburg, Russian Federation, 620014
elena.mayasina@gmail.com
Daniil F. Salimov
Head of Embryology Lab
Clinical Institute of Reproductive Medicine, LLC
B. Yeltsin Str., 3, of. 503, Yekaterinburg, Russian Federation, 620014
dfsalimov@mail.ru
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)